(A) CTCs isolated from a colorectal cancer patient. Three-color immunocytochemistry method based on FITC-labeled anti-CD45, PE-labeled anti-CK, and DAPI nuclear staining was applied to identify and enumerate CTCs from non-specifically trapped WBCs. (B) CTC enumeration results obtained from healthy donors and cancer patients. Numerical analysis of 4 patients showing the number of CTCs (red), concentration of serum CA19-9, CEA and tumor size (black) measured as the unidimensional sum of all significant tumor sites on a CT scan. Imaging studies were assessed by a single reference radiologist (Haibin Song), who graded responses according to Response Evaluation Criteria in Solid Tumors (RECIST). Type of treatment and duration are noted for each case. Patients with diagnoses and specific therapies shown are (C) patient 6, gastric, SOX: S-1 plus Oxaliplatin, (D) patient 22, colorectal, FOLFOX 6: Oxaliplatin, 5-FU and leucovorin, (E) Patient 7: gastric, SOX, f) Patient 19, colorectal, FOLFOX 6.